Alexandria Venture Investments contributed to a $91.5m round for Korro, which is working on RNA therapies for liver, eye and central nervous system diseases.
US-based RNA therapy developer Korro Bio completed a $91.5m a series A round yesterday featuring Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities.
The round was led by investment fund Wu Capital and included Atlas Venture, New Enterprise Associates, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management and MP Healthcare Venture Management.
Korro is developing drugs using an RNA editing platform called Opera which leverages enzymes in the body…
